A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of AMG145

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability and Pharmacodynamics of AMG145

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Evolocumab (Primary) ; Evolocumab (Primary)
  • Indications Hyperlipidaemia
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 15 Nov 2016 Results of pooled analysis from this and other study (20080397 and 20080398) assessing pharmacokinetic-pharmacodynamic relationship of evolocumab published in the Journal of Clinical Pharmacology.
    • 29 Mar 2012 Results presented at the 16th International Symposium on Atherosclerosis.
    • 02 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top